Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.

Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R.

Aliment Pharmacol Ther. 2012 Mar;35(5):587-99. doi: 10.1111/j.1365-2036.2011.04983.x.

2.

Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.

Lacy BE, Chey WD.

Expert Opin Pharmacother. 2009 Jan;10(1):143-52. doi: 10.1517/14656560802631319 . Review.

PMID:
19236188
3.

Lubiprostone: RU 0211, SPI 0211.

[No authors listed]

Drugs R D. 2005;6(4):245-8. Review.

PMID:
15991886
4.

Lubiprostone--a novel treatment for irritable bowel syndrome with constipation.

Owen RT.

Drugs Today (Barc). 2008 Sep;44(9):645-52. doi: 10.1358/dot.2008.44.9.1269852. Review.

PMID:
19137119
5.
6.

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003960. Review.

PMID:
17943807
7.

Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.

Ginzburg R, Ambizas EM.

Expert Opin Drug Metab Toxicol. 2008 Aug;4(8):1091-7. doi: 10.1517/17425255.4.8.1091 . Review.

PMID:
18680443
8.

Lubiprostone: in constipation-predominant irritable bowel syndrome.

Carter NJ, Scott LJ.

Drugs. 2009 Jun 18;69(9):1229-37. doi: 10.2165/00003495-200969090-00007. Review.

PMID:
19537839
9.

Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.

Chamberlain SM, Rao SS.

Expert Opin Drug Saf. 2012 Sep;11(5):841-50. doi: 10.1517/14740338.2012.708732. Review.

PMID:
22834474
10.

Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.

Schey R, Rao SS.

Dig Dis Sci. 2011 Jun;56(6):1619-25. doi: 10.1007/s10620-011-1702-2. Review.

PMID:
21523369
11.

Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.

Raschi E, De Ponti F.

Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):293-305. doi: 10.1517/17425255.2013.876410. Review.

PMID:
24387275
12.

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.

Shah E, Kim S, Chong K, Lembo A, Pimentel M.

Am J Med. 2012 Apr;125(4):381-93. doi: 10.1016/j.amjmed.2011.08.026. Review.

PMID:
22444104
13.

Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Li F, Fu T, Tong WD, Liu BH, Li CX, Gao Y, Wu JS, Wang XF, Zhang AP.

Mayo Clin Proc. 2016 Apr;91(4):456-68. doi: 10.1016/j.mayocp.2016.01.015. Review.

PMID:
27046523
14.

Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.

Thomas RH, Luthin DR.

Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Review.

PMID:
26016701
15.

New treatment targets for the management of irritable bowel syndrome.

Rao S, Weber HC.

Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):9-14. doi: 10.1097/MED.0000000000000034. Review.

PMID:
24300740
16.

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.

Vazquez Roque M, Camilleri M.

Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):301-10. doi: 10.1586/egh.11.30. Review.

PMID:
21651347
17.

Tegaserod for the treatment of irritable bowel syndrome.

Evans BW, Clark WK, Moore DJ, Whorwell PJ.

Cochrane Database Syst Rev. 2004;(1):CD003960. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD003960.

PMID:
14974049
18.

Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Wagstaff AJ, Frampton JE, Croom KF.

Drugs. 2003;63(11):1101-20. Review.

PMID:
12749744
19.

Lubiprostone: a chloride channel activator for treatment of chronic constipation.

Ambizas EM, Ginzburg R.

Ann Pharmacother. 2007 Jun;41(6):957-64. Review.

PMID:
17519292
20.

Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

Jadallah KA, Kullab SM, Sanders DS.

World J Gastroenterol. 2014 Jul 21;20(27):8898-909. doi: 10.3748/wjg.v20.i27.8898. Review.

Items per page

Supplemental Content

Support Center